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A STUDY ON SIGNIFICANCE OF HIGH SENSITIVE C-REACTIVE  
 
PROTEIN IN METABOLIC SYNDROME 
 
 
Background: Metabolic syndrome is an important risk factor predisposing to 
Coronary  
 
Artery Disease. HS-CRP, which is an inflammatory marker elevated in cases of  
 
Metabolic syndrome. 
 
Methods: We conducted a cross-sectional study signifying the relationship between  
 
high-sensitivity C-reactive protein (hs-CRP) with various components 
 
of metabolic syndrome in 50 patients with metabolic syndrome at our tertiary care  
 
centre in Tamilnadu. 
 
Results: CRP was significantly elevated in cases of Metabolic syndrome. On  
 
individual analysis hs-CRP was significantly elevated in women, in patients with  
 
Increased waist circumference and impaired glucose tolerance. There was no  
 
significant association between hs-CRP level and hypertensive status, Triglyceride  
 
levels and HDL levels. 
 
Conclusion: hs-CRP can be used as a surrogate marker of chronic inflammation in  
 
patients with metabolic syndrome 
 
Keywords: hs-CRP, metabolic syndrome. 
        1 
INTRODUCTION  
 
 The Metabolic syndrome (MS), also known as syndrome X or  
 
Metabolic Syndrome of Obesity is a combination of metabolic abnormalities  
 
which confers increased risk of cardiovascular disease (CVD) and 
 
Diabetes mellitus. 
 
 
 Pro-inflammatory state due to activation of macrophages and release of  
 
Cytokines by expanded adipocytes plays an important role in pathogenesis of  
 
this syndrome. This pro-inflammatory state can be documented by estimating  
 
the level C-Reactive Protein in serum. 
 
 Initially WHO proposed the criteria for defining Metabolic Syndrome in 
1988, which has now been evolved through these years; now currently accepted 
criteria for Metabolic Syndrome is based on the proposed definition given by 
National Cholesterol Education Programme: Adult Treatment Panel-III 
(NCEP:ATP-III) which simply is a constellation of multiple clinical and 
laboratory parameters. 
 
Diabetic Federation de Internationale also came with a new set of criteria 
defining Metabolic Syndrome, which is also practically in use in certain parts of 
world. Mainly European Diabetes Society is following the criteria proposed by  
            2 
IDF. Incidence and prevalence of this syndrome is variable depending on the 
criteria used for diagnosis. 
 
 Since the concept of inflammation gaining momentum we decided to 
evaluate the levels of high sensitivity CRP in metabolic syndrome. Out of all 
features of metabolic syndrome, obesity and HDL level were taken into 
particular consideration. Levels of high sensitivity CRP in obesity patients were 
analyzed thoroughly. Our study results were compared with existing studies all 
over the world and India.  
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AIM OF THE STUDY 
 
1.  Analysis of the proportion of patients with Syndrome X having elevated 
hs-CRP level in serum. 
2. To compare the levels of high sensitivity C Reactive Protein (hs-CRP) in 
obese and non-obese individuals of the study group.  
3. To assess whether obesity is a pro inflammatory state.  
4. To assess the correlation of high sensitivity C - reactive protein levels 
with individual parameters of syndrome X.  
5. Comparison of our study results with other Indian and foreign study 
results.  
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REVIEW OF LITERATURE 
 
              Metabolic syndrome  
 
 The combination of multiple risk factors predisposing to atherosclerosis 
has been named as metabolic syndrome. Names like “metabolic syndrome”, 
“insulin resistance syndrome”, “syndrome X” signifies a group of conditions 
present in a patient, which predisposes them to the risk of developing diabetes 
mellitus, coronary artery disease, cerebral vascular disease and peripheral 
arterial disease. Other synonyms commonly used are plurimetabloic syndrome, 
deadly quartet, CHAOS (Australia)2.  
 
History of metabolic syndrome  
 
 In the mid 1920's a researcher named Kylin described a disorder 
commonly found as a triad of Diabetes Mellitus, Hyperuricemia with associated 
joint disease and Hypertension as Metabolic Syndrome3.  
  
Study conducted in l'universite d'Aix-Marseille by researcher Jean 
Vague4 during the period of 1940-50 suggested that proportion of distribution of 
adipose tissue in human body reflects significantly with risk of developing 
 coronary artery diseases, NASH, peripheral vascular diseases, cerebral vascular 
diseases and hypertension rather than generalized obesity. Based on the 
observation they classified obesity into two categories.  
  
Android Obesity - also known as central obesity or apple-shaped obesity 
in which the deposition of fat tissues are seen mainly over central areas of body 
like waist. It is commonly seen in males.  
  
Gynoid Obesity - known as pear-shaped obesity in which deposition of 
fat in peripheral regions of body like hips, thighs. Such pattern of distribution is 
seen in females. 
  
They arrived at a conclusion that comorbidities associated with obesity 
are mostly seen in patients with Android type of obesity, whereas in gynoid 
obesity such comorbidities are never found. They also found that in patients 
with Central Android pattern of Obesity, there is a frequent association of type 
2 DM, hyperuricemia along with arthritis and renal stones, coronary artery 
diseases, NASH, peripheral vascular diseases, cerebral vascular diseases and 
hypertension. 
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Obesity - phenotypes described by Vague 
 
 
                                                               
                    Android obesity 
 
 
 
 
 
  Gynoid obesity 
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 In mid-1960's study conducted by researcher Avogadro et al5 in group of 
six individuals with significant obesity associated with Type 2 DM, 
dyslipidemia observed that when these persons were monitored strictly with 
providing reduced energy diet supplemented with diet having reduced 
proportions of carbohydrates resulted in significant improvement in blood sugar 
and normalization of lipids.  
 In 1970's, Haller mentioned that “metabolic syndrome” is associated 
with Type 2 DM, gout, NASH and dyslipidemia, while studying the comorbid 
illness found in patients vascular dysfunction6.  
  
At that period of time another study was simultaneously conducted by 
researcher Singer7, described association of hypertension with metabolic 
syndrome in addition to above mentioned components.  
  
Later in the same decade, Phillips proposed a theory that high risk groups 
of coronary artery disease usually show combination of comorbid illness which 
includes Type 2 DM, elevated insulin levels in serum, dyslipidemia like 
elevated triglycerides, low-density lipids and reduced high-density lipoproteins 
and hypertension. He also came up with a conclusion that these abnormalities 
are seen in old age and obesity in addition to myocardial infarction[8,9].  
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 In 1980, researchers from the Goldburg University on Europe analyzed 
the results of l’universite d'Aix-Marseille conducted by Jean Vague et al and 
went through their various publications, found that usage of simple bodily 
measurements provide significant clue in assessing the risk of developing 
cardiovascular illness, later came up new sensitive parameter for assessing 
proportion of fat distribution termed it as Waist-Hip ratio10.  
 Modan et al observed that elevated insulin level is a common factor 
found in association with each of the individual components of metabolic 
syndrome. Increased central obesity and impaired glucose tolerance was 
significantly related to elevated insulin levels in serum11. 
  
 Later some group researchers found simple primary hypertension alone 
can also be associated with hyperinsulinemia. Increased insulin levels 
significantly affects carbohydrate metabolism rather than fat or electrolyte 
metabolism. Such alteration of metabolism along with hyperinsulinemia is seen 
commonly in muscles, rest of appendicular tissues rather than in liver. Such 
altered metabolism correlates significantly with hypertension. 
  
In 1988, Banting lecture in the American Diabetes Association coined 
the term "syndrome X" and suggested that increased peripheral resistance to 
insulin is the fundamental defect. In that study there is nothing mentioned about 
8 
 central obesity, whereas it is proved that android obesity is one of the important 
component of metabolic syndrome13. 
 All these studies signified the importance of obesity and insulin 
resistance as the main etiological factor behind the development of metabolic 
syndrome. 
 
 
 
 
Syndrome X  
 
 
 
 
 
 
 
 
     
 
Increased TGL          increased insulin          reduced HDL        hypertension 
 
          
 Insulin resistance 
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Epidemiology 
 
 Incidence of metabolic syndrome is variable in various age groups and 
with ethnicity. It shows a linear correlation with age. It rises from 20 to 50 years 
and plateaus later off.  
 NHANES III study14 observations concluded that nearly 25 percentage 
of people more than 18 years of age in North America found to be having 
metabolic syndrome. They fulfilled the individual parameters necessary for 
developing Metabolic Syndrome. 
 
 According to two studies on obesity in India the prevalence of metabolic 
syndrome ranges from 8% in men to 46% in women15. Both these studies used 
population based samples within the age range. Yet there was significant 
difference in the prevalence of metabolic syndrome, ranging from 13% in 
Jaipur16 to 41% in Chennai17. 
 
 Another study conducted in Chennai18 observed that the incidence of 
Metabolic Syndrome was around 12% which correlates with results of study 
conducted in Rajasthan. This study make use of European Criteria published in 
1999, known as European Group for the study of Insulin Resistance Syndrome 
10
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 criteria. Hence it shows that though people belong to same race or community 
there appears to be significant variations in incidence of syndrome X and its 
various components of the syndrome separately when measured alone.  
 In late 1990's World Health Organization came up with common 
definition for this disorder applicable to all group of people living in various 
regions of the world and coined the term Metabolic Syndrome. Currently 
accepted and followed criteria is proposed by National Cholesterol Education 
Program (NCEP) - Adult Treatment Panel (ATP III. 
 
WHO 
 
WHO criteria19: 
 
Essential components 
  
 Type 2 Diabetes Mellitus 
  
 Impaired glucose tolerance,  
 
 Impaired fasting glucose or insulin resistance  
 
AND two of the following:  
11 
  
 Systolic BP > 140 or Diastolic BP>90 mm Hg 
 
 Altered fat metabolism 
            Serum TGL > 150 mg/dL 
 
             Serum HDL   
 
    < 35 mg/dL in men 
    < 39 mg/dL in women  
 
  Obesity   
    WHR  > 0.90 in men  
 
     > 0.85 in women  
  Or 
    Quatelet index > 30kg/m2 
 
 Micro albuminuria - urinary albumin excretion ratio > 20mg/min 
 
    Or albumin: creatinine ratio > 30mg /g 
 
12 
  
 
 European Group for study of Insulin resistance definition for 
Metabolic Syndrome (EGIR 1999)19 
 - Proposed criteria mainly give importance to Insulin resistance, 
hence it is also called as Glucocentric criteria 
Components are: 
1. Peripheral resistance to Insulin or elevated insulin level in serum 
 (Plasma insulin more than 75th percentile).  
 
Any two of the below 
 
1. Obesity: Waist circumference  
> 102cm (men)  
> 88cm (women)  
2. Lipid derangement: 
 Sr. TGL > 2 mmol/L   or  
 Sr.HDLC <1 mmol/L  
3. Hypertension   
Systolic BP > 140 or 
 Diastolic BP > 90 mmHg 
4. Fasting Blood sugar > 110 mg/dl 
13 
  
The US National Cholesterol Education Program Adult Treatment Panel 
III (2001) requires at least three of the following20 
 
1. Blood pressure   Systolic > 130 or Diastolic BP > 85 mm Hg or on 
    anti-hypertensive drugs 
2. Fasting blood sugar   > 110mg/dL or on oral hypoglycemics or  
     known case of Type 2 DM  
3. Plasma triglyceride   > 150mg/dL or specific medication  
4. Plasma HDL   
Male   < 40mg/dL or specific medication  
   Female < 50mg/dL 
6. Waist circumference 
     Male > 102cm  
        Female  > 88cm 
 
Presence of three or more of the above risk factors constitute metabolic 
syndrome.  
 
Modified NCEP 2004 changed the existing cutoff level of fasting plasma 
glucose to > 100mg/dL. 
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American Heart Association / NHLBI (2005)21 
 
1. central obesity 
 Males – > 102cm  
 Females  – > 88cm    
 
2. Increased TGL: > 150 mg/dL 
 
3. Low HDL-C:  
Males – < 40 mg/dL 
 Females – < 50mg/dL 
 
4. Hypertension: 
 Systolic BP > 130 or Diastolic BP > 85 mm Hg or when the patient is on 
antihypertensive.  
 
5. Impaired glucose tolerance:  
Fasting blood sugar > 100mg% or when the patient is hypoglycemic 
agents.  
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IDF Criteria for abdominal obesity22 
 
IDF came up with new set of criteria which is in use in European countries and 
some Diabetic associations in Europe 
 
 
 
 
International diabetic federation has proposed the following recommendations 
for central obesity.  
 
Waist 
Circumference  
   
Men  Women  Ethnicity   
>94cm  >80cm  Europid, Sub-Saharan African, 
Eastern & Middle Eastern  
>90cm  > 80cm South Asian, Chinese and ethnic 
South & Central American  
>85cm  > 90cm  Japanese  
Two or more the following  
16 
 Fasting triglycerides > 150 mg/dL or specific medication  
HDL cholesterol <40mg/dL and <50mg /dL for men and women, respectively, 
or specific medication  
Blood pressure > 130 systolic or > 85 mm diastolic or previous diagnoses or 
specific medication 
Fasting plasma glucose > 100mg/dL or previously diagnosed type 2 diabetes 
 
 
Etiology of metabolic syndrome is not clearly understood. Basic pathogenesis 
of this syndrome is very confusing.  
Important risk factors are: 
 
1. Old age  
2. Hereditary and  
3. Sedentary habits  
 
Still there is a controversy existing between researches regarding the 
etiology of metabolic syndrome .Some group proposes insulin resistance as the 
basic defect for development of metabolic syndrome. Other group strongly 
suggests obesity as the underlying etiology in development of metabolic 
syndrome. Very few authors says that both the obesity and insulin resistance are 
due to rather advanced systemic abnormalities.  
17 
  
Almost all the study results showed that when insulin resistance is absent 
then the persons will not show features of metabolic syndrome, but not all the 
patients with syndrome X will be having obesity. 
 
Pro-inflammatory cytokines are found to be elevated in patients with 
metabolic syndrome. Common observed ones are interleukin 1, 6 and 18; C - 
reactive protein; TNF-alpha, resistin;  
 
Pathophysiology  
 
Abdominal adipocytes secretes numerous fatty acids, angiotensin-II and 
adipokines into circulation25. The increase in free fatty acids26 reduces the 
uptake of glucose by muscle27. Excess free fatty acids and angiotensin II are 
harmful to pancreas and causes destruction of acini28. Although pancreas 
manufactures excess insulin, it is just not enough to counter fasting 
hyperglycemia. This explains the paradox of fasting hyperglycemia in spite of 
increased plasma insulin levels in insulin resistance syndrome. Changes 
associated with metabolic syndrome are,  
 
1. Lipoprotein – increase in apo B, Lp (a)  
18 
 2. Prothrombotic state – increase in fibrinogen, Plasminogen activator 
inhibitor 1  
3. Inflammatory markers – increase in CRP, TNF, IL 6 
4. Vascular – micro albuminuria 
5. Increase in serum uric acid, homocysteine 
6. Nonalcoholic fatty liver disease  
7. Obstructive sleep apnea  
8. Polycystic ovaries  
 
 
 
Obesity – Is it a disease???  
 
The current developments in health sciences look at obesity as a starting point 
of all disease process.  
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 According to WHO the global burden of obesity and overweight is projected as 
follows.  
In 2005:  
Nearly around 16,000 million persons above 15 years of age were having 
BMI > 25; 
 
 Around 4 billion were found to have obesity.  
In 2015: 
 
  
  Over 19,000 million persons over 18 years were having BMI > 25;  
 
Among them over 6 million were obese. 
 
 40% of persons over 18 yrs of age have BMI > 25 and 13% were  
 
Having BMI > 30. 
 
Most of the world's population live in countries where overweight and  
 
Obesity kills more people than underweight. 
 
42 million children under the age of 5 were overweight or obese in 2013. 
 
Obesity is preventable. 
 
 At least 20 million children under the age of 5 years are overweight globally in 
2005. 
 
Initially thought to be a disease of developed countries, now incidence 
and prevalence of obesity and insulin resistance were showing increasing trends 
20 
 in developing and under-developed countries mainly because adopting western  
lifestyles.  
 
Energy consumption and energy expenditure are important determinants 
in developing obesity. When there is disparity in consumption of calories and 
amount of calories spent by the patient by routine daily activities predisposes to 
the development of obesity.  
 
Rising trends in prevalence of obesity is due to,  
 
Global shift in diet towards increased intake of energy – dense foods that 
are high in fat and sugars but low in vitamins, minerals and other 
micronutrients; and  
 
A trend towards decreased physical activity due to the increasingly 
sedentary nature of many forms of work, changing modes of transportation, and 
increasing urbanization.  
 
 Height, weight and Waist circumference are the key determinants in 
estimating obesity. Most important index used to define Obesity is body mass 
index (BMI), also known as the Quetelet index. Body Mass Index nearly 
reflects the amount of body fat in many persons, which is measured as  
21 
 Weight in Kg/Height square in meters. 
 
 The Deurenberg equation is used to estimate the body fat percentage as 
follows: body fat percentage = 1.2 (BMI) (+ 0.23 (age) – 10.8 (sex) – 5.4, where 
age is in years and sex is 0 for female and 1 for male.  
 
The international Classification of adult underweight, overweight and obesity 
according to BMI (adapted from WHO 2005).  
But there is a slight change in this proposed criteria which is in use in India.   
Based on which classification of obesity is defined. Below mentioned 
classification is the international standard criteria.  
 
 World Health Organization proposed a strategy on Lifestyle 
modifications like Food habits, exercise and health, which promotes practices 
which need to be followed in order to obtain good quality of food and carry out 
routine exercise. 
 
The proposal encourages all medical and paramedical staffs to carry out 
all necessary measures at international, national and community level in order 
to decrease incidence of non-communicable diseases and also to give significant 
importance to primary prevention strategies for eliminating the modifiable 
factors responsible for those diseases. 
22 
  
 
 
 
 
   
Proposed strategy by World Health Organization is a component of their 
Chronic Disuse Control guidelines under the separate area of health network for 
non-communicable disease prevention under the control of WHO 
23 
WHO CRITERIA FOR OBESITY 
 Goals of this strategy are: 
 
i. Educate all people about non-communicable disease control 
measures;  
ii. Adequate importance must be given for people below the poverty line 
iii. Controlling the modifiable risk factors thereby retarding the 
progression of chronic diseases;  
iv. Reducing the mortality and morbidity associated with chronic 
diseases.  
 
Major health sectors are also supporting this project by framing the refined 
objectives accordingly, which is based on regional requirements.  
  
They are mainly focusing on people who are more prone for developing these 
non-communicable diseases and educating them to take properly and adequately 
nourished food, recommending exercise schedule based on their preferences 
through promotional campaigns, posters, advertisements in the media and 
routine health camps. 
 
 They also help underdeveloped nations by financial assistance in order to 
frame and implement programmes necessary to achieve the strategic goals in 
addressing the issues related to diet and health. Majority of such programmes 
24 
 being conducted in African and Asian countries under various levels, still the 
prevalence of chronic diseases are on rise. But some sectors of health related 
activities showing good progress, they will be able to reach goals in the near 
future.  
 
 Hence, in the eyes of WHO and various other health groups obesity is a 
burden on health and a possible disease process. It is now seen as an ongoing 
inflammatory process which, like diabetes, leads to increase in the 
cardiovascular morbidity and mortality. Hence, obesity is considered as an 
important component of metabolic syndrome and as an independent risk factor 
for cardiovascular disease.  
 
 
 
Physical inactivity 
 
 
Sedentary life habits are important determinants to develop metabolic  
 
syndrome.  It also predisposes the patients in  
 
developing dyslipidaemia, insulin resistance and obesity which are the  
 
individual  parameters of metabolic syndrome. Increase in physical exercise was  
 
one important lifestyle modification in primary and secondary prevention of  
 
metabolic syndrome.  
 
 
 Studies shows persons who involve in sedentary activities  
 
25 
 like playing video games and spending time in internet have  
 
increased risk of developing metabolic syndrome, when compared  
 
with those who do physical exercises for more than 30 minutes daily. 
 
 
Assessing the level of physical activity  
 
Physical activities are assessed in various ways by the type of  
 
activity , timing and hours spent on such activities, and also by  
 
ecological conditions of the place where they carry out such activities. 
 
Other than physical exercise, energy expenditure is also based on the 
 
Occupation, whether it is associated with workload, continuous strain or  
 
Intermittent strain and the person’s choice of recreation, mode of recreation.  
  
 
Various methods in which quantification of physical activity can be done 
 
are 
 
 Indirect calorimetric method 
 
 Accelerometer method using sensors 
 
 Physical activity associated heart rate variation assessment 
 
 Self-reporting estimation method 
 
Type of method of assessing the physical activity is individualised  
 
according to targets, study group size, financial resources, social factors and 
 
also reliability of the methods. 
 
 
Accurate modes of measuring amount of energy expenditure  
26 
  
are water labelling method and calorimetric method. But they are not  
 
practically useful for measuring a large group of population, hence in such  
 
conditions self-reporting method is used, though they are not as sensitive and  
 
specific as instrument dependant methods.  
 
 
 
 
 
Indirect calorimetric method 
 
 
Most sensitive and precise method of assessing energy expenditure 
 
and calories spent during rest and with rest.  
 
Two steps in the assessment of energy spent using indirect calorimetric  
 
method are 
 
First the expired air is collected in closed container like airtight  
 
Container or plastic bag. 
 
Second, the open system in which measurement of amount of energy  
 
Spent are quantified over prolonged period.  
 
Depending upon the person’s respiratory activity, the energy spent are assessed  
 
by the formula 
 
REE = [VO2 (3.94) + VCO2 (1.11)] 1440 min/day 
 
Where 
 
 REE = resting energy expenditure, 
 
 VO2=oxygen consumption &  
27 
  
VCO2 =carbon dioxide production. 
 
This formula reflects amount of oxygen consumption and carbon-di-oxide 
 
Production is closely related to energy expenditure. 
 
But this method is practically not feasible.  
 
 
Double-labelled water method: 
 
  
This method utilizes radio-labelled isotopes for assessing energy  
 
expenditure.  Study group of people were given a dose of heavy water and 
 
they will receive normal water of about 15-20 ml. 
 
After a period of fasting of about 8 hours, baseline urine sample was  
 
collected for 0-hour isotope measurement.  
 
2nd urine sample will be taken after four hours of giving radio-isotope. 
 
This sample measures total body water. 
 
3rd sample will be taken after 24 hours of isotope administration time. 
 
From then on, at least 2 samples of urine has to be collected from the starting  
 
and finishing time of the study in order to estimate the amount of energy 
 
spent. Normal period of study is 3 weeks.  
 
 
The daily food intake is noted during the observation period and the diet  
 
remains the same throughout the study for the most accurate results and the  
 
respiratory quotient (RQ) calculated based on daily intake. Any body  
 
fluids will be useful assessing the space, but preferred specimen is urine 
28 
  
due to methods used for collection are not cumbersome. 
  
 
Accelerometer: 
 
 
Accelerometer estimates amount of acceleration gained with fall.  
 
The instrument is positioned upper or lower parts of body usually at the 
 
Bony prominence. This method is used to differentiate the variation in levels of  
 
activity among different persons and estimate the level of changes that can be 
 
made by introducing any intruding things. 
 
 
For type every action carried out, persons will be given specific  
 
Basic Score. They are as follows 
 
Sedentary activity - < 800/min  
 
Mild workload – 800-3199/min  
 
Medium workload – 3200 – 8200/min and  
 
Severe workload - > 8201/min 
 
 Metabolic equivalent value is assessed by using an equation having  
 
parameters like age of the patient and score obtained by them. 
 
 
Heart rate variation estimation method: 
 
 
Heart rate variation of the patient while doing physical exertion is  
 
Estimated in this method. Usually heart variation is directly proportional 
 
to the amount of workload, which in turn gives objective evidence of amount 
29 
  
of energy spent by the patient.  
  
 
Leads are placed around the thorax which will be having a Bluetooth 
 
Communication with wristwatch for monitoring the activity. 
 
Main endpoint is measured as duration of time required to perform an action 
 
when the patient is in baseline heart rate or converting the heart rate  
 
into baseline level. By this method the amount of energy spent is indirectly  
 
measured using specific equation. 
 
 
Since there are multiple factors which can cause increase in heart rate 
 
it may lead to confounding bias resulting inaccurate estimation.  
 
 
 
 
 
Self-reporting method: 
 
 
One of the commonly employed ways of assessing physical exertion 
 
which are also known as interview-method.  
 
 
Questions are prepared by using various studies, which assess the 
 
individual level of activity with correspondence to their social background  
 
are in use. They estimate the amount of energy spent based on available log  
 
of questions. Usually it is done retrospectively by asking workload during 
 
past one month and roughly estimating the amount of energy spent. 
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There are multiple ways of assessing the activity. Commonly it is  
 
based on the duration in which longer duration recall for example for  
 
one month period givers overall idea about type of manoeuvres the people in  
 
particular social background are following. Whereas the small duration  
 
questioning method is used for epidemiological surveys which gives the  
 
photograph of the population under study.  
 
 
Pathophysiology of obesity  
 
The pathogenesis of obesity is simply not an imbalance between energy 
intake and energy output, it is far more than that. Although this concept allows 
easy understanding of the various mechanisms involved in the development of 
obesity, obesity is simply not the result of too much eating and/or too little 
exercise.  
 
 Two major factors that are variably involved in the development of 
obesity are genetics and environmental factors. Off springs are at increased risk 
of obesity when both parents are obese and in monozygotic twins there is 
increased prevalence of obesity. 
 
 
31 
 Leptin: 
 
Leptin is a protein synthesized and secreted mainly by adipocytes plays 
an important role in regulation of body weight. 
 
Leptin was discovered by Freidmen in 1990, following which there is 
increase in wide variety of studies based on leptin was conducted resulting 
understanding it major role in controlling satiety cycle and food intake. The 
term leptin suggests “Thin” in Greek. 
 
 Initially it was thought that food intake and satiation is controlled by 
ventromedial nucleus and limbic system of hypothalamus, which was later 
proved that neurological control of satiety is more advanced and confusing 
process difficult to understand. 
 
  
Leptin functions by signaling hypothalamus regarding satiety thereby 
resulting in decreased food intake, also decrease in storage of body fat thus 
causing reduction in body weight. It also protects against gaining weight due to 
action on altering the metabolism of carbohydrates and burning excessive 
calories.  It is found that obesity is mainly due to resistance to action of leptin 
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 not due to its deficiency. Thus most obese individuals are found to have 
increased serum leptin levels. 
 
 Recent studies have found that leptin is a member of the cytokine family 
with a helical structure. Helical cytokines are a diverse family of proteins 
without any detectable sequence of homology between its members. All these 
cytokines are found to have a four helix bundle that exhibits an up-up-down-
down folding pattern. Interleukin-2, interleukin-4, granulocyte-macrophage 
colony-stimulating factor, macrophage colony-stimulating factor, and grown 
hormone are the helical cytokines identified. 
  
Leptin binds to its receptor which belongs to family of cytokines. Janus 
Kinase activates the receptor resulting in transduction of signal. 
 
 By acting centrally on the melanocortin receptor 4 (MC 4) 
Proopiomelanocortin and alpha melanocyte stimulating hormone reduce the 
dietary intake.  
 
 There are several genes encoding Proopiomelanocortin, mutation in any 
of these genes causes reduced synthesis of alpha – melanocyte – stimulating 
hormone. Decreased melanin level in such patients causes presence of red hair. 
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 In addition to that they have absent ACTH in blood causing secondary 
deficiency of adrenals resulting in obesity. Studies suggests that 4-6% of obese 
individuals who are under age group of 10 found to have these mutations. 
More than 10 different loci has been identified and these mutations accounts for 
major cause of genetic associated obesity. 
 
 Leptin activates PC-1 processing enzyme which plays an important role 
in the conversion of POMC to alpha – MSH. Peroxisome Proliferator Activator 
Receptor-gamma is responsible for differentiation of fat tissue cells. If mutation 
is found in this receptor such patients will be invariably associated with obesity.  
 
 Various other genetic disorders associated with obesity are Cushing’s 
syndrome, Hypothyroidism, Insulinoma, Craniopharyngioma and other 
hypothalamic disorders. Cushing due to genetic defect can be differentiated 
from routine Cushing’s syndrome by measuring cortisol levels in blood and 
urine in basal state and response to CRH, which will be normal in them. Subtle 
hypothalamic dysfunction is the major cause of obesity which can be confirmed 
by radiological studies. 
  
Growth hormone level is found to be decreased in patients with obesity 
probably as a result of compensatory suppression to increased nutrition supply 
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 Role of Leptin 
 
Central pathway of leptin mechanism of action is signaling of POMC 
neurons in hypothalamus resulting in synthesis of alpha-MSH which needs to be 
processed by PC-1 enzyme. Alpha-MSH binds with melaocortin-4 receptors 
causing reduced appetite. AgRp known as Agouti-related peptide is an 
antagonist to the same receptor   
 
 Obese Mice or ob/ob mice have mutated ob gene, such mice will eat 
excessively due to deficient signal control by inadequate leptin affecting 
neurohormonal control of satiety resulting in extreme obesity. This analysis 
suggested use of Leptin as a treatment option for obese individuals having 
deficient leptin due to various hereditary diseases causing excessive and 
abnormal appetite. Such patients also show reduced activity of t-lymphocytes, 
immunodeficiency, dyslipidemia, impaired fasting glucose tolerance and 
various other endocrinological defects.  
 
 Blood leptin amount vary between day and night, commonly elevated at 
night. Various cytokines, insulins and Ang-II causes release of leptin from 
adipose tissue. Increased level suggests expanded adipose tissue mass and vice-
versa.  
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 5 genetic defects in pathway of leptin action are found to be associated 
with obesity. They are mutation in leptin synthesizing gene, receptor mutation, 
POMC mutation, melanocortin-4 receptor mutation and PC-1 processor 
mutation.  
 
 
CRP AN INFLAMMATORY MARKER 
 
CRP – An inflammatory Marker  
 
Inflammation is the mechanism by which human protects itself against various 
noxious substances. Absence of which causes poor recovery of traumatized 
tissues and inability to fight against multiple pathogens resulting in further 
damage to organs. 
 Any injury to organs results in inflammation which is followed by acute 
phase response, which is normal physiological phenomenon occurs when there 
is infection or inflammation. The response is characterized by various 
components including fever, enhanced permeability of vessel wall and 
alteration in level of numerous active substances in blood known as acute phase 
reactants. 
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 Adipocyte derived- macrophages are the important source of pro-
inflammatory cytokines. The pro-inflammatory cytokines are increased in 
number which are interleukin 1, 6 and 18; resistin; TNF-alpha and serum bio-
marker C - reactive protein. Elevated cytokine level reflect over-production of 
expanded adipose tissue mass.  
 
 CRP is a biological substance which was known as an acute phase 
reactant for long. From that it has progressed on to be known as an important. 
Inflammatory marker.  
Table – 1  
Acute – phase proteins  
 Increased concentration  Decreased concentration  
Protease inhibitors  Alpha1 – antitrypsin   
 Antichymotrypsin  
Coagulation proteins  Fibrinogen   
 Prothrombin  
 Factor VIII   
 Plasminogen   
Complement proteins  C1s, C2, C3, C4, C5 
Factor B  
C1 esterase inhibitor  
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 Plasminogen  
Transport and storage 
proteins  
Haptoglobin Transferrin  
 Haemopexin  
 Caeruloplasmin  
 Ferritin   
Miscellaneous C – reactive protein  
Procalcitonin 
Serum amyloid protein  
Fibronectin 
Alpha1 – acid 
glycoprotein  
Albumin  
Pre albumin  
 
 CRP is one of the important factor in protection from various infection. It 
got its name from its activity against C antigen in Streptococcus pneumonia. 
Initially it was thought to be an antibody reacting against the C-antigen. But 
after various research it is found to be a separate protein reacting with bacterial 
antigen. Level of CRP will return to normal once the infection subsides. CRP 
binds with carbohydrate moiety like choline present in the surface of cell 
surface of various pathogens  
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  Reaction of CRP with C-antigen causes activation of classical 
complement pathway and opsonization of specific antigenic components for 
phagocytosis.   
 
 CRP is mainly produced and released by hepatocytes after an 
inflammatory reaction in body. Release of CRP is promoted by various 
cytokines predominantly by IL-6. Peak level in serum occurs after 6 hours of 
inflammatory process initiation, which may around thousand-fold. Half-life of 
CRP is around 10-30 hours, hence once the inflammatory process subsideslevel 
of CRP will fall rapidly. In normal personslevel of CRP ranges from 0.9 mg/L – 
2.05 mg/L, which will never increase above 5mg/L. Elevation of CRP level 
above 40mg/L is found in case cell necrosis and bacterial infections. 
 
 CRP levels are found to be reduced in case of liver failure and renal 
insufficiency which will adversely impact the results 
 
CRP in clinical setting  
 
 Increased CRP level does not signify any particular pathology, usually 
increased in inflammatory states (>95%), helpful as an indicator of 
inflammatory state. It provides a supportive evidence in routine workup of a 
39 
 patient.CRP level assessment is a useful screening tool, which will signify the 
severity of disease process. 
 
Conditions in which elevated C-Reactive protein level is seen are 
 
Table 2  
 
Bacterial infections  Pyelonephritis  
 Pelvic infections  
 Meningitis  
 Endocarditis  
Hypersensitivity  
Complication of infections  
Rheumatic fever  
Erythema nodosum 
Inflammatory disease  Rheumatoid Arthritis  
Juvenile Chronic Arthritis  
Ankylosing Spondylitis  
Psoriatic Arthritis  
Systemic Vasculitis 
Polymyalgia Rheumatica 
Reiter’s Disease  
Crohn’s Disease  
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 Familial Mediterranean Fever  
Transplantation  Renal Transplantation  
Cancer  Lymphoma  
 Sarcoma  
Necrosis  Myocardial Infarction  
TumourEmbolisation 
Acute Pancreatitis  
Trauma  Burns  
Fractures  
 
 Certain conditions are found to have very minimal elevation of CRP 
though there is an evidence of inflammation. They are 
Table 3  
 
Inflammatory disease  Systemic Lupus Erythematosus 
Systemic Sclerosis  
Dermatomyositis 
Ulcerative Colitis  
Sjogren’s Syndrome 
Transplantation  Graft Versus Host Disease  
Cancer  Leukemia 
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 In these situations CRP levels are near normal, in spite of having evident 
high grade inflammatory activity. Pathology behind this process is not fully 
understood. 
 
 In certain diseases like RA, CRP levels are helpful in assessing 
candidate’s improvement in clinical status after initiating treatment. Mainly in 
RA, CRP level correlates significantly with active disease process and also their 
response to treatment. Other uses of CRP measurement includes very high 
elevation of the reactant is seen in bacterial infection rather than viral infection, 
thus providing a supportive evidence of bacterial pathology.  
 
   C - reactive protein is more likely to be highly elevated  
(More than 100mg/dl) in bacterial rather than viral infection, and it is unlikely 
to see a normal C – reactive protein in the presence of significant bacterial 
infection.  
  
C - reactive protein levels are usually remain constant even with usage of 
NSAIDS or changes in body temperature. So they play a supportive role in 
clinical assessment in combination with fever charts clinically. In certain 
diseases like SLE still there confusion exists in differentiating disease flare up 
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 or new onset infection. In such situations measuring CRP level is vital in 
establishing the presence of infection. 
 
 Increased C - reactive protein concentration can affect higher 
mental functions which includes learning and memory. Various studies 
confirmed the fact that in patients with dementia or other defects in cognition 
there is significant rise in the concentration of C - reactive protein in serum. 
Advanced studies were conducted in past years which proposed a theory that 
early rise in blood level of hsCRP found to be good predictor of dementia in old 
age females.  
  
A new study investigating CRP in patients with chronic obstructive 
pulmonary disease (COPD) indicates this inflammatory marker to be elevated in 
patients with this lung disease. When researchers measured levels of CRP and 
the proinflammatory cytokines tumor necrosis factor – alpha (TNF – alpha) and 
interleukin – 6 (IL – 6) in COPD patients they found that CRP was the only 
inflammatory marker studied that was elevated in subjects with stable COPD. 
According to the study authors, “The present study confirms that circulating 
CRP levels are higher in stable COPD patients and may thus be regarded 
as a valid biomarker of low-grade systemic inflammation”. 51 
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High Sensitivity C reactive protein  
 
High-sensitive C - reactive protein – the term indicates the test used to estimate 
even the minute changes in CRP level over a normal prescribed range. Hence it 
is a valuable and sensitive indicator of inflammatory state. Routine latex 
agglutination test CRP measurements are not very sensitive in diagnosing early 
stages of vascular dysfunction in atherosclerosis. 
 
High sensitive CRP measurement estimate cardiac risk status in a visibly 
normal individual when used in combination with lipid profile.  
 
 Till now 34 case-control studies demonstrated association between hs-
CRP and increased risk of atherosclerosis, 9 prospective study result showed hs-
CRP level correlates with prognosis of patients in the metabolic syndrome and 
risk of developing diabetes mellitus.  
 
AHA/CDC define the risk group as follows 
 
1. Low risk   <0.1 mg/dL 
2. Average risk   0.1 to 0.3mg/dL 
3. High risk   > 0.3mg/dL 
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The relationship between hs-CRP and the components of 
 
the metabolic syndrome: 
 
 
Elevation in concentrations of CRP in cases of obesity and also in  
 
Persons with metabolic syndrome have been reported in various studies  
 
that too in amounts which were considered as very high risk by researchers 
 
across the various nations.   
 
 
C-Reactive protein level not only reflects the inflammatory  
 
Activity and also directly proportional to parameters of metabolic  
 
Syndrome. There are various researches which were carried out to  
 
establish the relationship between C - reactive protein level and multiple  
 
components of metabolic syndrome. 
 
 
A retrospective study on normoglycemic patients conducted 
 
by Yudkin and others proposed that each component of obesity is  
 
associated with increase in C-reactive protein level. 
 
It also reflects the risk of developing impaired glucose tolerance,  
 
Hypertension, dyslipidaemia and other features related to vascular  
 
Defects like atherosclerosis. The researchers came out with a conclusion  
 
proposing adipocytes are major stimulator of inflammatory activity 
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 which will predisposes them in developing impaired glucose tolerance and 
 
atherosclerosis. They also suggested that these activities acts as a bridge  
 
between impaired glucose tolerance , atherosclerosis and cardiac and other 
 
systemic complications. 
 
  
 
A retrospective study conducted in Tunisia proposed the importance 
 
of central obesity as an individual important determinant of CRP levels in  
 
patients with metabolic syndrome of both sex. Decrease in HDL-C level in 
 
metabolic syndrome especially in women associated with significant rise in  
 
CRP level.  
 
 
In an another retrospective study conducted in Israel also came out with 
 
with conclusion that in each parameters of metabolic syndrome C-Reactive  
 
protein will be elevated, especially in individuals with central obesity  
 
showing higher correlation. Through this researchers proposed that 
 
important factor in metabolic syndrome that signifies inflammatory activity 
 
is waist circumference. They also pointed out that obese individuals who are  
 
not having metabolic syndrome are also at high risk of death due to cardiac  
 
illness.   
 
 
A study conducted in Germany which used BMI rather than waist  
 
circumference also proposed that C-Reactive protein level is directly  
 
proportional and significantly associated with each of the individual parameters  
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of metabolic syndrome. P-value of this study if found to be <0.0001. They also  
 
showed that with rising numbers of parameter of syndrome X, there will be  
 
significant rise in serum levels of C-Reactive protein.  
 
 Atherosclerosis remains the major cause of death in developed regions 
of the world. Patients develop clinical features depending on site of lesion of 
atherosclerosis. When it affects coronary arteries it causes MI and angina, in 
cranial vessels results in stroke, limb vessels results in peripheral arterial 
disease, renal vessels causes renal artery stenosis, aorta causes aortic aneurysm, 
splanchnic vessels cause mesenteric ischemia. Even though C-Reactive protein 
predicts the risk of atherosclerosis , studies showed it does not promote 
atherogenesis, which is in contrast to lipoprotein-a and apolipoproteinc3 which 
promotes atheroma formation. 
 
 Increasing evidence suggests elevated hsCRP predicts risk of 
coronary artery disease. Increased levels of these markers correlates with 
increased inflammatory state. After death post-mortem studies in myocardial 
infarction patients showed features of inflammation like deposition of chronic 
inflammatory cells at regions of infarction. These findings shows C - reactive 
protein estimation correlates with stages of development of atheroma formation.  
 
47
48 
  Recent studies conducted which are based on statins like JUPITER study 
and PROVE-IT study showed treatment with statins reduced cardiovascular 
mortality in patients showed reduction both CRP and lipoprotein level, rather 
than reduction in either one alone. Mechanism by which statins reduce these 
CRP level is unknown. Adipocytes of viscera secretes inflammatory mediators 
which promotes CRP synthesis, important region of CRP production in persons 
with obesity. Increased CRP levels correlates with increased BMI and increased 
adipocyte thickness in visceral organs. Loss of body weight is associated with 
reduction in CRP levels. 
 
CRP estimation  
 
Initially latex agglutination method was used in estimating CRP level which has 
poor sensitivity in estimating minimal rise in C - reactive protein. Hence 
proposal for usage of CRP as an indicator of inflammatory state was rejected 
earlier. 
 
 The estimation of CRP was earlier done by ELISA. It threw light into a 
possibility of CRP being more than just an acute phase reactant. It suggested 
that normal persons have CRP levels for below the normal cut off value and 
higher values are associated with increased cardiovascular risk.  
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  Later highly sensitive nephelometry and turbidometry commercial kits 
are being used in the estimation of CRP. 
 
 While measuring hs-C-Reactive protein, things which are taken into 
consideration are exclusion of any inflammatory state, sepsis, tissue injury etc. 
If present, then the test should be performed only after two weeks of recovery of 
sepsis. Sensitivity of test increases with two assays which are done with a gap 
of four week period, risk assessment is done through smaller value. Usage of C 
- reactive protein estimation for selecting persons for pTCAis under research. 
 
CRP Aids Risk Stratification  
Persons with this syndrome are more prone cerebrovascular disease, 
intervening at starting stage of disease itself carries good prognosis. C – 
Reactive protein (CRP) is an indicator of low-grade inflammation which 
estimates the risk of myocardial infarction, cerebro-vascular disease and death 
due cardiac illness in normal persons with no history of vascular disease, and 
among individuals with acute or stable coronary disease, CRP predicts recurrent 
events and death.  
 
 In the Study on Health indicators of Women, elevated C-Reactive protein 
levels are good indicators of the individual parameters of the metabolic 
syndrome and metabolic syndrome as a whole.  In various analyses, if the CRP 
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 level is less than 1mg/L it has significant correlation with risk free benefit 
related cardiac illness.  
  
Various studies across the the world came with conclusion that in 
patients fulfilling the criteria for syndrome X will also have carbohydrate 
metabolism dysfunction which are dependent on insulin. But in reality it is 
confirmed that all cases obesity are not associated with glucose intolerance and 
they show discrete clinical features. Study conducted by Reaven et al., showed 
that hyperinsulinemia and peripheral insulin resistance is found in patients with 
syndrome X.  
 
 Central obesity plays an important role in development of insulin 
resistance. Amount of visceral adipose tissues correlates significantly with 
peripheral resistance to insulin when compared to subcutaneous adipose fat 
mass. Triglycerides are synthesized by reaction between glycerol and fatty 
acids, which go and get deposited in adipocytes. In condition requiring energy 
these triglycerides undergo beta-oxidation of fatty acids and releases energy. In 
individuals with obesity fatty acids are produced in excess which gets deposited 
in adipose tissue. It leads onto expanded fat mass, commonly in visceral organs 
providing favorable conditions for developing insulin resistance. 
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 Chronic inflammatory states are associated with increased vascular 
complications like atheroma and fibro atheroma formation. Such states may also 
promotes development of peripheral resistance to insulin, which will further 
aggravates inflammatory burden. Hence measurement of CRP level correlates 
significantly with patients having syndrome X, high risk grading based on 
serum level and assessing the response to treatment.   
 
Inflammation, obesity and CRP  
 
Obesity is mostly associated with moderate amount of inflammatory 
activity certified by presence of elevated hs-CRP and inflammatory mediators 
released by macrophages. All these changes will lead on vessel wall changes 
involving endothelium, promoting atherosclerosis. These features can possibly 
somewhat explain the development coronary artery diseases in patients with 
increased fat mass. 
 
Pathophysiology underlying the development of vascular damage in 
obese individuals is not completely understood. Proposed theories are adipose 
tissue secrete numerous immunologically active substances known as 
“adipocytokines”, which modulates the inflammatory activity in various tissues. 
Thus they may cause significant mortality due to cardiac illness. 
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  Various studies showed that factors present in subcutaneous and visceral 
adipose tissues secrete multiple immunological substances which are 
responsible for increased risk of mortality related to cardiac illness. These kind 
of pathological activities are found to be increased in obesity patients. Such 
immunological substances are called as "adipocytokines", since they are 
secreted from adipocytes 
 
Adiponectin 
 
Adiponectin is a hormone synthesized and released mainly from adipose 
tissues. Main functions of this hormone is found to be enhancing insulin 
sensitivity, promoting oxidation of lipids. It is also found to be vaso-protective. 
Obese individual have very low level of adiponectin in their circulation. Reason 
for this reduced level is not known.  
 
 There are various ways in which hormone adiponectin acts in the 
body. In each of these ways it undergoes a conformational change and carry out 
its role. The mechanism by which it undergoes such structural change and 
subsequent physiological following structural change is not clearly defined. In 
muscle tissue they promote beta-oxidation of fatty acids and in liver they cause 
inhibition of gluconeogenesis and promote glycogenesis. 
 
52 
  With raising incidence of obesity in the industrial world, various 
ways and tests by which we can detect the risk obesity in early stage itself and 
other comorbidities are also on the rise. 
 
Based on various studies and researches it has now been understood that 
adipocytes are not just a mass of fat stores, but it is an endocrine organ secreting 
various hormones. Individual hormones which are secreted by adipose tissues 
and their functions are not completely studied. 
 
The state of chronic inflammation typical of obesity occurs at 
metabolically relevant site such as liver, muscle and adipose tissue. Increased 
inflammatory marker IL – 6, associated with obesity might interfere with 
insulin action by suppressing insulin signal transduction which, in turn 
interferes with anti – inflammatory effects of insulin.  
 
Leptin, an adipocyte specific protein is elevated in obese, has 
proaggregatory effect on platelets and also elicit inflammatory responses. Hence 
obesity is considered to be a pro inflammatory state and inflammatory markers 
like CRP and TNF are elevated in isolated obese individuals.  
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 Studies supporting obesity as a major determinant of CRP in metabolic  
Syndrome  
              Steven and zinnman (ADOPT Trial), was conducted in 1999 in view of 
determining the microvascular and macro vascular complications and related 
comorbidities in association with obesity or hypertension. They have also found 
that metabolic syndrome is more prevalent in recently diagnosed diabetics even 
if there is no confounding factors. It is commonly seen in relation with very 
high inflammatory activity and defect in clot retraction pathways. 
 
 The metabolic syndrome is most common with type 2 diabetes, and 
cerebrovascular accidents are more common in individuals with metabolic 
syndrome than subjects with type 2 diabetes who do not have the metabolic 
syndrome. Furthermore, higher levels of c reactive protein, fibrinogen and PAI-
1 in non-diabetic subjects has been associated with metabolic syndrome.77 
 
Obesity plays an important role in mediating these effects, and insulin 
resistance has an added effect.  
 
William et al 78 analyzed the association between C Reactive Protein, 
obesity and the metabolic cardiovascular risk factors. The authors demonstrated 
an association between CRP and BMI, in young men and women, independent 
of the other cardiovascular risk factors. As this study was conducted only in a 
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 group of women and men aged 26 years and did not use a high sensitivity assay 
for C Reactive protein measurements, leads to a potential underestimation of 
differences among study groups with low CRP concentrations.  
 
Clinical research article published in Circulation 2004 and supported by 
American Heart Association concludes, that CRP was strongly related to all 
anthropometric and direct measures of total and central abdominal obesity. 80, 
81 
 
Margit Froehlich, Armin Imhof et al found an association between the 
acute-phase marker CRP and a number of disorders characterizing the 
metabolic syndrome. They concluded that the metabolic syndrome is associated 
with a systemic inflammatory response, which pays an important pathogenic 
role in atherothrombotic disease. 82 
 
Christine and. Mukkammal carried out a study on obesity in the year 
2007 to march 2009, in which they proposed that increased BMI in spite of 
variations in race, nationality and community including both males and females 
were found to have elevated level of CRP in serum. The p-value of the results 
were adjusted for age groups, lifestyle practices and nationality/ racial variation 
, sex , even after the changes which were made in measurement CRP values 
were found to be persistently elevated.  
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According to Madric84 study, CRP levels are significantly elevated in 
patients with metabolic syndrome and NCEP protocol and C-Reactive 
concentrations in serum correlates significantly with central obesity.  
 
A study conducted by some researchers in Japan proposed in both male 
and female sex level of C-Reactive Protein correlates significantly with 
syndrome X. In the same study they concluded that rise in C-Reactive Protein 
was significant more in females that too  non-smokers who are already having 
the predisposing factors of metabolic syndrome.  
 
Ridker, Buring et al 86 have observed that measurement of CRP adds 
clinically important prognostic information to the metabolic syndrome.  
 
Studies not supporting obesity as a major determinant of CRP in metabolic  
Syndrome  
 
Tracey McLaughlin, FahimAbbasi, et al 87 (Circulation 2006) observe that 
CRP concentrations are elevated predominantly in obese individuals who are 
also insulin resistant and fall is parallel with weight loss – associated 
improvements in insulin resistance. The relation between CRP concentrations 
and insulin resistance is independent of obesity.  
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MATERIALS AND METHODS 
 
 
 
 
 
 
 Materials and Methods  
 
The study was conducted in Thanjavur Medical College Hospital, 
Thanjavur, and Tamilnadu. The study was conducted in the Department of 
Internal Medicine. The study period extended between June 2007 and October 
2008. It was a carefully selected study population of metabolic syndrome. 
National Cholesterol Education Program Adult Treatment Panel III (ATP III) 
criteria was used to define metabolic syndrome in the study group.  
 
 The patients were selected on the basis of inclusion and exclusion 
criteria. In all those patients, high sensitivity C-reactive protein was estimated 
and analyzed. The study included both sexes. Fifty patients were included in the 
study group after applying exclusion criteria. The sample population was 
predominantly obtained from the patients attending the diabetic and 
hypertension clinic and medicine outpatient department of our hospital.  
 
 This is a cross sectional population based study. The study population 
was selected randomly among the out patients. Out of the many definitions 
applied worldwide for metabolic syndrome, the ATP III guidelines is the only 
which has been approved and accepted by many quarters. It is the one which 
has been extensively used in the clinical trials of metabolic syndrome too. 
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 Hence, we applied the NCEP/ATP guidelines (with current modification) for 
selecting the study group.  
 
Definition of terms  
Obesity was defined as a BMI > 30kg/m2 (WHO 2000)  
Metabolic syndrome – presence of at least three components among the major 
five parameters in the criteria proposed by the National Cholesterol Education 
Program Adult Treatment Panel III  
 
1. Central obesity (waist circumference > 88cm in women and > 102cm in 
men).  
2. Low serum HDL cholesterol (<50mg/dL in women and < 40 mg/dL in 
men) or on specific medication,  
3. High serum triglyceride (> 150 mg/dL) or on specific medication,  
4. Elevated blood pressure (>130 mmHg systolic / > 85 mmHg diastolic) or 
on specific medication, 
5. Abnormal glucose homeostasis (fasting plasma glucose > 100 mg/dL) or 
on specific medication or previously diagnosed type 2 diabetes.  
 
Inclusion criteria 
 The patient should fit into the definition of metabolic syndrome as 
defined by ATP III guidelines, as given above.  
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Exclusion criteria  
Past history of coronary artery disease  
Past history of cerebrovascular accidents 
Patients with  
1. Active infection  
2. Inflammation  
3. Neoplasm  
4. Autoimmune / Collagen vascular disease  
5. Pregnancy  
6. Terminal illness  
7. Smokers  
8. Renal and hepatic dysfunction  
Were excluded from the study. 
 A proforma was drafted including the details about the patient and 
specifically related to known risk factors and factors that can elevate hs – CRP.  
 
Physical examination  
The patients underwent routine physical examination and anthropometric 
measurements.  
 
Waist Circumference and Weight & Height calculation: 
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 In patients wearing very loose clothing, without any footwear and 
measured weight was rounded off to multiples of 100 grams. 
Measurement of height was done by using WHO proposed protocol with 
making the patients stand without any footwear. This method is the commonly 
followed one all over the world. 
 Body mass index (BMI) was calculated by body weight in kilogram 
divided by square of height in meters.  
 
 Waist circumference – it is measured at midpoint between lower costal 
margin and highest point of iliac bone in mainly around the widened region of 
gluteus using a measurement tape which is circled over the abdomen without 
any wrinkles and stretching. While measuring there should not be any pressure 
on the surface of body. Values are rounded off to nearest 1 mm. Quality of the 
tape is to be in such way that it should not be too elastic and too rigid.   
 
Assessment of biomarkers  
Levels of fasting glucose, HDL-C, and triglycerides were determined by 
enzymatic methods using an auto analyzer, whereas hs-CRP levels were 
measured by latex-enhanced nephelometry (Fully Automated Nephelometry BN 
100).  
 
Estimation  
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 The sample was withdrawn after a period of overnight fasting. 5ml of venous 
blood was collected in a sterile glass tube. The blood was allowed to clot 
centrifuged and analyzed for high sensitivity CRP levels using 
NEPHELOMETRY method. A value of > 0.3mg/dL was taken as a positive hs-
CRP in our clinical study.  
 
Nephelometry 
It is a method which measures the amount of photon energy which were 
scattered by the particulate matter using a sensor rather than measuring the 
photon energy in straight line with the light source. Most of the instruments 
measures the energy usually at 90 degrees to light source, while some others 
Measures at angles lesser than 90 degrees. 
 
 There are lot of ways in which protein level can be estimated. Among 
them most important one is Nephelometry. It is useful in assaying various 
proteins such lipoproteins, CRP, RA factor, ASO titer, various components of 
complement system. Other methods which are useful are Turbidometry, Biuret 
method. 
 
Lowest range at which turbidimetry can detect and protein level is 
around 30 microgram/milliliter. But Nephelometry can detect and assay protein 
even up to 10 microgram/milliliter. Thus nephelometry is method of choice in 
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 detecting and assaying proteins when there is a need for monitoring even minor 
variation in their serum level. 
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RESULTS AND ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 RESULTS AND ANALYSIS   
 
The study sample included fifty patients, male and female. The age of the study sample 
ranged from 30yrs to 77yrs.  
 
Incidence  
 
Age in years 30-39    40-49 50-59 60-69 >70  
No of Cases 3(6%) 14(28%) 19(38%) 10(20%) 4(8%)  
 
 
 
 
Figure 1  
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  The study sample included 18 males and 32 females  
 
SEX NO. OF CASES PERCENTAGE 
MALES  18 36% 
FEMALES  32 64% 
 
AGE BASED CLASSIFICATION OF PATIENTS 
 
 
 
Figure 2  
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 The high sensitivity CRP levels are classified according to cardiovascular risk 
status as 
<0.1   mg/dL  low risk  
0.1-0.3 mg/dL  average risk 
>0.3  mg/dL  high risk  
 
Hs – CRP levels 
mg/dL 
No. of Males No. of Females 
<0.1 0 0 
0.1-0.3 (12%) 8(16%) 
>0.3 3(6%) 32(64%) 
 
 
Most of the research projects takes the hs-CRP levels of > 0.3 mg/dL as a 
positive result. In this study too, we have taken any value above 0.3 mg/dL as 
positive level. Hence, out of the sample group of 50 patients 42 (84%) showed 
an increase in hs-CRP levels and 8 (16%) showed levels <0.3 mg/dL. Out of the 
42, 29 were females and 13 were males.  
 
 No. of Males No. of Females 
Positive hs-CRP (>0.3 
mg/dL) 
13 (26%) 29 (58%) 
Negative (<0.3 
mg/dL) 
5(10%) 3(6%) 
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HS-CRP RELATION WITH SEX 
 
 
Figure 3  
 
 
 
 
 
 
 
The association between hs- CRP levels and individual components of 
metabolic syndrome was analyzed.  
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 The study sample of 50, included 41 subjects with increased waist 
circumference (>90 cm in males and > 80cm in females). Out of the 41, 39 had 
hs – CRP levels of > 0.3 mg/dL, whereas only 3 of the remaining 11 with waist 
circumference (<90 cm in males and < 80cm in females) had levels of > 0.3 
mg/dL.  
 
 
 
 
 
 
Increased Waist 
Circumference 
41 (82%) 
Normal waist 
circumference 
9 (18%) 
hs-CRP> 3.0 
mg/dL 
39 3 
hs-CRP <0.3 
mg/dL 
2 6 
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 HS-CRP IN RELATION WITH CENTRAL OBESITY 
 
 
 
Figure 4 
 
 
 
 
 
 
 
 
 
The study sample of 50, included 38 subjects with low HDL levels. (<40 mg/dL 
in males and < 50mg/dL in females). Out of the 38, 32 had hs – CRP levels of > 
0.3 mg/dL and 6 of the 19 with high HDL levels > 0.3mg/dL.  
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HS-CRP IN RELATION WITH HDL 
 
 
Figure 5 
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 The study sample of 50, included 28 subjects with triglyceride levels of > 150 
mg/dL and 22 had levels lesser than it. Out of the 28, only 20 had hs – CRP 
levels of > 0.3mg/dL; whereas all 22 of the 22 with lower triglyceride levels 
had levels of >0.3 mg/dL.  
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 Our study sample of 50, included 41 subjects with blood pressure > 130/85 
mmHg. Out of the 41, hs- CRP levels were above 0.3mg/dL in 34 subjects. In 
the non-hypertensive group of 9, hs-CRP was elevated in 8 subjects.  
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Figure 7 
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The current guideline used for fasting blood sugar was > 100mg/dL instead of 
the previous level of > 110mg/dL. We employed the current guideline in 
defining raised blood sugar levels in the sample group. Out of the 50 members 
of the study group 40 had impaired fasting glucose or known diabetic and 10 
had normal glucose. In the group of 40, 34 had an elevated hs-CRP and among 
the 10, 5 had an elevated hs-CRP.  
 
 Impaired fasting glucose 
40 (80%) 
Normal 7 (14%)  
hs-CRP > 0.3 mg/dL 34 5 
hs-CRP < 0.3 mg/dL  6 5 
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HS-CRP IN RELATION WITH IMPAIRED GLUCOSE TOLERANCE 
 
 
Figure 8 
 
 
 
 
The study sample of 50, included 41 subjects with BMI > 30kg/m2. Out of the 
41, 33 subjects had hs-CRP levels > 0.3mg/dL. Of the remaining 9, 2 subjects 
had elevated levels of hs-CRP.  
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HS-CRP IN RELATION WITH BMI 
 
 
Figure 9 
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Analysis of results  
 
The results were analyzed with confidence interval testing and using chi – 
square test.  
 
a) The levels of high sensitivity CRP are higher in metabolic syndrome. Using 
the confidence interval method, 42 of the 50 have high hs- CRP levels and it 
falls outside the confidence interval of 0.95. Hence the study result is consistent 
with the claim that hs- CRP levels are high in metabolic syndrome.  
 
b) In this study population of 18 male and 32 female, 13 male and 29 females 
showed increase in hs – CRP levels.  
 
 Using the chi – square hypothesis, the null hypothesis that there is no 
difference in hs – CRP levels between two sexes is disproved in this study. In 
this there is a definite evidence (p < .002) that females with metabolic syndrome 
has high hs – CRP when compared to males.  
 
c) The study sample of 50, included 41 subjects with central obesity (waist 
circumference > 90cm in males and > 80 cm in females). Out of the 41, 39 had 
hs – CRP levels of > 0.3 mg/dL, whereas only 3 of the remaining 9 with normal 
waist circumference had levels of > 0.3 mg/dL.  
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  Using chi – square test, a p value of <0.001 (strongly significant) was 
derived. This is a telltale evidence that out of all the components of metabolic 
syndrome, hs – CRP levels depend on waist circumference significantly. Hence, 
obesity is an independent inflammatory state on itself.  
 
d) The study sample of 50, included 38 subjects with low HDL levels. (< 40mg 
/dL in males and < 50 mg /dL in females). Out of the 38, 32 had hs – CRP 
levels of > 0.3 mg/dL and 10 of the 12 with high HDL levels had levels of > 
0.3mg/dL.  
 
 Using chi –square test, a p value of 0.336 (insignificant) was derived. 
Hence, changes in plasma HDL levels do not affect the levels of hs – CRP in 
metabolic syndrome.  
 
e) The study sample of 50, included 28 subjects with triglyceride levels of > 
150 mg/dL and 22 had levels lesser than it. Out of the 28, only 20 had hs – CRP 
levels of > 0.3mg dL; whereas 22 of the 22 with lower triglyceride levels had 
levels of >0.3mg/dL.  
 
 Using chi – square test, a p value of 0.696 (insignificant) was derived. 
This means that elevation of hs – CRP levels in metabolic syndrome is 
independent of plasma triglyceride levels.  
 
f) In this study sample of 50, 41 were hypertensive. Out of the 41, hs – CRP 
levels were above 0.3mg/dL in 34 subjects. In the non – hypertensive group of 
9, hs – CRP was elevated in 8 subjects.  
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  Using chi – square test, a p value of 0.614 (insignificant) was derived. 
This means that elevation of hs – CRP levels in metabolic syndrome is 
independent of hypertension.  
 
g) Out of the 50 members of the study group 40 had abnormal glucose 
homeostasis (impaired fasting glucose) and 10 were normal. In the group of 40 
subjects, 34 had an elevated hs – CRP and among the 10 normal subjects, 5 had 
an elevated hs – CRP.  
 
 Using chi – square test, a p value of 0.128 (moderate significance) was 
derived. This means that elevation of hs – CRP levels in metabolic syndrome is 
moderately dependent of glucose status.  
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Discussion  
 
Analysis of hs – CRP levels in patients with metabolic syndrome.  
 
Inference 1  
This study shows statistical evidence that hs – CRP levels are elevated in 
metabolic syndrome.  
 
The above inference is supported by the studies of  
 
 Margit Frohlich, Armin Imhof et al82 
 MADRIC84 study – CRP levels are significantly elevated in patients 
with metabolic syndrome 
 
Ridker, Buring et al86.  
 
Inference 2  
 
In our study, hs - CRP levels in women with metabolic syndrome is 
significantly higher when compared to levels in men with metabolic syndrome. 
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 Though there are not many studies approving or disproving this result, the 
following studies support it.  
 
 Study by Noriyuki Nakanishi, Tsunehito Shiraishi, Mariko Wada et 
al, and 85 states that an increase in CRP concentration is more pronounced in 
women.  
  
 Martin K. Rutter, James B. Meigs, et al88 have stated that elevated 
CRP levels are related to insulin resistance and the presence of the metabolic 
syndrome, especially in women.  
 
Inference 3  
 
Levels of hs – CRP are strongly associated with changes in waist circumference 
and the p value derived was < 0.001, an indication of its strong association. This 
inference is supported by many other studies which support obesity as an 
independently inflammatory state.  
 
 According to MADRIC84 study, metabolic syndrome and all its 
individual components were associated with high CRP levels, with the strongest 
association being found for high waist circumference (P <0.001).  
  
 Clinical research article published in Circulation 2004 and supported by 
American Heart Association concludes that CRP was strongly related to all 
anthropometric and direct measures of total and central abdominal obesity.  
 
Inference 4  
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 Levels of hs – CRP are independent of plasma HDL levels in metabolic 
syndrome. In this study, there is no statistical significance between the levels of 
plasma HDL and hs – CRP.  
 
This inference is supported by,  
Margit Frohlich, Armin Imhof, et al82 and  
MADRIC84 study 
 
 
Inference 5  
Levels of hs – CRP is independent of Plasma triglycerimia levels. This is one 
inference in our study which does not correlate with the results of other studies.  
 
 Margit Frohlich, Armin Imhof, et al82 in a population based study has 
concluded that there is a statistically significant correlation between plasma 
TGL levels and hs – CRP levels.  
 
 In our study 12 values of plasma TGL lies between 140-150 mg/dL 
which could have contributed to the discrepancy in the results when compared 
to other studies. This needs to be studied further.  
 
Inference 6  
Levels of hs – CRP in metabolic syndrome does not depend on the  
hypertensive status of an individual. This statement derived from our study is 
supported by,  
 
 Steven E, Kahn, Bernard Zinman et al.,76 ADOPT, A Diabetes 
Outcome Progression Trial – where even in non-diabetic subjects the metabolic 
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 syndrome has been associated with higher levels of CRP as well as PAI – 1 and 
fibrinogen.77 
 
Inference 7  
Levels of hs – CRP does have a moderately significant association with diabetic 
status of the individual. In our study there is moderate statistical significance (p 
-0.126) between the diabetic status and hs – CRP. This statement derived from 
our study is supported by,  
 
 Tracey and Fahim et al.,study where they suggested insulin resistance  
is significantly associated with elevated levels of CRP independent of obesity. 
 
 Steven E, Kahn, Bernard Zinman et al.,76 ADOPT, A Diabetes 
Outcome Progression Trial – where even in non-diabetic subjects the metabolic 
syndrome has been associated with higher levels of CRP as well as PAI – 1 and 
fibrinogen.77 
 
 
Inference 8  
Levels of hs – CRP does have a significant association with Body Mass Index. 
In our study there is statistical significance (p <0.001) between the BMI and hs 
– CRP.  
 
This inference is supported by,  
 
Margit Frohlich, Armin Imhof, et al82. 
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  CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Conclusion  
 
1. The levels of serum hs – CRP are elevated in metabolic syndrome.  
2. The levels of hs – CRP are significantly elevated in obese individuals.  
3. Obesity is a pro – inflammatory state all by itself.  
4. Levels of hs – CRP are significantly elevated in patients with central 
obesity.  
5. Levels of hs – CRP is slightly dependent of blood glucose in patients 
with metabolic syndrome.  
6. Levels of hs – CRP is higher in women metabolic syndrome than men 
with metabolic syndrome.  
7. Levels of hs – CRP is independent of plasma triglyceride levels in 
patients with metabolic syndrome.  
8. Plasma HDL levels will not affect the levels of hs – CRP in metabolic 
syndrome.  
9. Levels of hs – CRP is independent of hypertensive status in patients with 
metabolic syndrome.  
10. Our study results are comparable with other Indian and foreign study 
results.  
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FUTURE  
 
Patients with metabolic syndrome have higher levels of hs – CRP than those 
without this syndrome. Patients with elevated hs – CRP levels of > 0.3mg/dL 
are considered to be at a higher risk for the development of cardiovascular 
events than others.  
 
 According to Framingham score this hs – CRP level is associated with a 
ten year risk of coronary heart disease of 10-20%. Risk stratification by hs – 
CRP gives prognostic information in patients with metabolic syndrome.  
 
 Patients with metabolic syndrome and elevated hs – CRP values should 
be subjected to an appropriate life style modification at an early age, treatment 
with low dose aspirin, lipid lowering medications, non-pharmacological 
modifications and global education. This study opens up new avenues for 
further research in the topic of the ever changing field of metabolic syndrome.  
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 PROFORMA 
Name     Age      Sex  
Occupation  OP NO  
Address  
Diagnosis  
Presenting complaints   
Past history  HT     DM    Malignancy  
   CVA     CAD    Renal disease  
   Autoimmune   Hyperlipidemia 
   Collagen vascular  
   Disease  
Personal history   Smoker    Alcohol 
Physical examination  BP   Systolic         mmHg 
      Diastolic        mmHg 
    PR-  
    Height(cm)  Weight(kg)   BMI Kg/m2 
    Waist circumference cms  Hip circumference cms 
    Waist/hip ratio 
Investigations 
Hb gm%   TC    DC   RBC   PCV   ESR 
Urine    Albumin   Sugar     Deposits 
Fasting blood sugar   mg/dL  
Blood urea  mg/dL      Sr. Creatinine mg/dL  
ECG        LFT  
Sr. TGL mg/dL  Sr. HDL mg/DL   USG Abdomen  
hs- C reactive protein   mg/dL   CT abdomen 
  
 
     ABBREVIATIONS 
 
MS  - Metabolic Syndrome 
 
ATP-III - Adult Treatment Panel III 
 
IDF  - International Diabetic Federation 
 
hsCRP - High sensitive C-reactive Protein 
 
NHANES III - National Health and Nutrition Examination Survey 
 
EGIR  - European Group for study of Insulin Resistance 
 
HDLC - High Density Lipoprotein Cholesterol 
 
LDL  - Low Density Lipoprotein 
 
TGL  - Triglycerides 
 
BMI  - Body Mass Index 
 
WHO  - World Health Organization 
 
JAK/STAT - Janus Kinase 
 
ACTH - Adrenocorticotropic Hormone 
 
POMC - Proopiomelanocotin 
  Alpha-MSH - Alpha Melanocyte Secreting Hormone 
 
TNF-alpha - Tumour Necrosis Factor Alpha 
 
CVD  - cerebrovascular disease 
 
CAD  - Coronary Artery Disease 
 
PVD  - Peripheral Vascular Disease 
 
NASH - Non-Alcoholic SteatoHepatitis 
 
MI  - Myocardial Infarction 
 
ADOPT - A Diabetes Outcome Progression Trial 
 
FCRS  - Framingham Coronary Heart Disease Risk Score 
 
NCEP  - National Cholesterol Education Program 
 
 
 
 
 
 
  NAME Age/Sex Waist Circumference            BP        
FBS 
Sr.HDL 
mg/dl 
Sr.TGL hs-
CRP 
1 FATHIMA 50/F 80            
140/90 
142 52 195 0.57 
2 MEENA 55/F 124            
150/100 
178 34 220 1.1 
3 AROCKIA SAMY 77/M 104            
140/100 
126 41 135 0.63 
4 BALAGURU 45/M 108            
160/110 
163 40 118 0.51 
5 BARATHI 62/F 118            
120/80 
192 39 170 1 
6 BANUSHANKAR 45/M 127            
140/90 
118 44 95 2.1 
7 BASKARI 42/F 110            
150/90 
126 58 210 0.45 
8 GUNASEKARAN 49/M 90            
170/110 
178 35 140 1.3 
9 JAMIMA 30/F 86            
150/100 
95 31 210 0.11 
10 JEYAKUMAR 60/M 110            
140/90 
130 40 125 1.78 
11 JEYALAXMI 55/F 120            
130/90 
140 56 110 1.3 
12 JOSEPHINE 59/F 88            
160/90 
122 33 170 0.99 
13 KALYANI 60/F 109             
180/110 
147 29 220 1.3 
14 KARUNA 40/F 100            
150/90 
154 43 165 0.89 
15 MANI 60/M 117            
150/110 
126 47 90 1.65 
16 MANGALAM 45/F 77            
120/80 
138 32 210 0.24 
17 MANICKAM 73/M 87            
140/90 
87 36 245 0.17 
18 NAGARAJAN 62/M 122            
160/110 
118 42 150 2.12 
19 NARAYANI 43/F 98           130/80 92 45 165 1.11 
20 NOORAHMED 45/M 108 150/100 158 41 115 1.3 
21 PADMAVATHI 53/F 100 140/110 195 37 155 1 
 22 PANDIAMMAL 50/F 92 110/80 232 42 135 0.55 
23 PONMANI 48/F 118 110/70 86 45 180 1.32 
24 POUNAMBAL 40/F 114 150/100 190 45 155 0.46 
25 PREM 63/M 88 150/100 82 31 205 0.11 
26 SOBIN 63/M 92 130/80 212 30 145 1.72 
27  RANI 55/F 129 170/90 80 41 120 2.15 
28 MANOJ 50/M 121 160/90 260 35 160 3 
29 SAMIPILLAI 50/F 109 180/100 124 37 105 0.55 
30 SAROJA 60/F 99 160/90 95 39 205 1.53 
31 SAROJA 45/F 113 130/70 148 40 95 0.58 
32 SEEMA 39/F 74 150/100 166 32 130 0.79 
33 SELVAM 49/M 102 160/90 129 39 115 1.5 
34 SELVARANI 70/F 81 160/100 189 33 135 1.65 
35 SHANTHI 52/F 78 150/100 84 37 170 0.19 
36 SUBRATHA 39/F 114 110/70 114 35 155 0.57 
37 SUSAI MARY 60/F 118 140/100 173 34 200 0.99 
38 SURESH 55/M 85 160/120 250 32 195 0.21 
39 THARA 43/F 120 100/60 155 41 175 1.22 
40 THANGAMANI 52/F 96 140/80 131 29 85 0.68 
41 MANOHARI 55/F 119 140/110 166 33 100 0.74 
42 LALITHA 50/F 104 160/90 82 44 110 0.85 
43 VASANTHA 
PRIYA 
56/F 89 160/100 118 39 155 0.71 
44 VASANTHA 56/F 123 130/80 172 38 165 0.51 
45 VEERALAXMI 51/F 106 120/80 132 43 150 1.36 
46 KRISHNAMMAL 55/F 120 140/100 127 32 95 1.54 
47 VELLAISAMY 77/M 124 150/90 148 37 210 1.33 
48 RAJAVEL 52/M 102 150/100 130 36 170 0.78 
49 VIJAY 48/M 94 160/110 93 48 190 0.25 
50 SUGUMAR 60/M 83 150/100 130 43 165 0.28 
 
  
    CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR .R.THILAKH  BABU, Post graduate in the 
Department of  General Medicine ,Thanjavur Medical College & Hospital, Thanjavur 
– 613004 and to use my personal clinical data and result of investigation for the 
purpose of analysis and to study the nature of disease. I also give consent for further 
investigations 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
 
